LIVE
PRGO
Perrigo Company plc · Health Care - Generic Pharmaceuticals & Consumer Health
$10.25
-0.88% this month
VERSUS
⟷
COMPARE
AMGN
Amgen Inc. · Health Care - Biotechnology
$337.60
+2.07% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
PRGO
2
AMGN
2
Comparison scoreboard
MIXED SETUPAI Score
PRGO 24.1
AMGN ✓47.3
1Y Return
PRGO -58.64%
AMGN ✓+16.39%
Fwd P/E
PRGO ✓4.34
AMGN 15.13
Target Up.
PRGO ✓+60.98%
AMGN -0.76%
Op. Margin
PRGO N/A
AMGN 33.80%
Metrics last refreshed: 6/20/2026
Quick take
PRGO vs AMGN Stock Comparison: AI Score, Valuation, Performance and Upside
PRGO (Perrigo) is a private label OTC healthcare manufacturer serving the value-seeking end of the consumer health market, while AMGN (Amgen) is a major innovative biotechnology company developing premium branded biological medicines. These companies operate at opposite ends of the pharmaceutical value chain with very different margins, growth profiles, and risk characteristics.
PRGO vs AMGN contrasts the private-label generic pharmaceuticals and consumer health model against one of the world's largest innovative biotechnology companies, representing opposite ends of the pharmaceutical investment spectrum.
Live analysis · updated 6/20/2026
PRGO and AMGN are closely matched — they split the tracked metrics evenly. AMGN has delivered stronger 1-year price return (+16.39% vs -58.64%), though PRGO trades at the lower forward P/E (4.34x vs 15.13x). Analyst consensus implies meaningfully more upside for PRGO (+60.98%) than for AMGN (-0.76%).
Normalized 1Y performance
PRGO
AMGN
Recent returns
PRGO
AMGN
Analyst price targets & sentiment
PRGO · 4 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.4/5.0)
Price target range
analyst low$14.00
analyst high$20.00
analyst mean$16.50
current price$10.25
+61.0% upside to analyst mean
AMGN · 28 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.4/5.0)
Price target range
analyst low$185.00
analyst high$400.00
analyst mean$352.50
current price$337.60
-0.8% upside to analyst mean
Who should consider this stock?
PRGO may suit investors who:
- →Want exposure to the private label consumer health segment benefiting from retailer preference for higher-margin store brands
- →See Perrigo's strategic refocus on consumer self-care as creating a cleaner, more focused business with recovery potential
- →Value the recession-resilient nature of OTC consumer health spending as a defensive consumer staples-adjacent investment
AMGN may suit investors who:
- →Want one of the largest, most diversified biotechnology companies with a growing portfolio across oncology, cardiovascular, and inflammation
- →Value Amgen's durable free cash flow and consistent dividend payment as a quality large-cap biotechnology income investment
- →See biosimilar revenue as an additional growth pillar alongside Amgen's branded innovative portfolio
Performance & AI score
| Metric | PRGO | AMGN |
|---|---|---|
| AI score | 24.1 | 47.3 |
| AI rank | #3287 | #625 |
| Latest close | $10.25 | $337.60 |
| 1M return | -0.88% | +2.07% |
| 6M return | -19.52% | +3.56% |
| 1Y return | -58.64% | +16.39% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | PRGO | AMGN |
|---|---|---|
| 1Y ago | $4.4K (-56.0%) started 2025-06-18 | $11.66K (+16.6%) started 2025-06-18 |
| 5Y ago | $3.33K (-66.7%) started 2021-06-18 | $18.29K (+82.9%) started 2021-06-21 |
| 10Y ago | $1.85K (-81.5%) started 2016-06-20 | $39.81K (+298.1%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | PRGO | AMGN |
|---|---|---|
| Market cap | $1.42B | $191.7B |
| Trailing P/E | N/A | 24.68 |
| Forward P/E | 4.34 | 15.13 |
| Price/Sales | 0.34 | 4.57 |
| EV/Revenue | 1.18 | 6.37 |
| Analyst target | $16.50 | $352.50 |
| Target upside | +60.98% | -0.76% |
Growth, profitability & risk
| Metric | PRGO | AMGN |
|---|---|---|
| Revenue growth | -7.20% | 5.80% |
| Earnings growth | N/A | 4.40% |
| EPS growth | N/A | +4.40% |
| FCF margin | +2.59% | +19.98% |
| Operating margin | N/A | 33.80% |
| Profit margin | -43.50% | 20.96% |
| ROIC proxy | -52.23% | 101.32% |
| Return on equity | -52.23% | 101.32% |
| Dividend yield | 11.42% | 2.84% |
| Beta | 0.52 | 0.42 |
| Debt/equity | 153.22 | 623.75 |
| Current ratio | 2.72 | 1.26 |
| Quick ratio | 1.09 | 0.85 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
PRGO max drawdown66.32%
AMGN max drawdown16.57%
PRGO max wkly drop30.59%
AMGN max wkly drop8.70%
5Y risk snapshot
PRGO max drawdown77.73%
AMGN max drawdown24.86%
PRGO max wkly drop30.59%
AMGN max wkly drop12.81%
10Y risk snapshot
PRGO max drawdown88.00%
AMGN max drawdown24.86%
PRGO max wkly drop35.26%
AMGN max wkly drop15.79%
Performance metrics by period
| Period | Metric | PRGO | AMGN |
|---|---|---|---|
| 1Y | Growth | -58.64% | +16.56% |
| CAGR | -58.67% | +16.59% | |
| Sharpe ratio | -1.75 | 0.53 | |
| Max drawdown | 66.32% | 16.57% | |
| Max daily drop | 25.21% | 5.84% | |
| Max wkly drop | 30.59% | 8.70% | |
| 5Y | Growth | -73.10% | +59.69% |
| CAGR | -23.10% | +9.83% | |
| Sharpe ratio | -0.66 | 0.32 | |
| Max drawdown | 77.73% | 24.86% | |
| Max daily drop | 25.21% | 7.14% | |
| Max wkly drop | 30.59% | 12.81% | |
| 10Y | Growth | -86.24% | +193.14% |
| CAGR | -18.00% | +11.36% | |
| Sharpe ratio | -0.46 | 0.38 | |
| Max drawdown | 88.00% | 24.86% | |
| Max daily drop | 29.28% | 9.58% | |
| Max wkly drop | 35.26% | 15.79% |
Business comparison
| Category | PRGO | AMGN |
|---|---|---|
| Company | Perrigo Company plc | Amgen Inc. |
| Sector | Health Care - Generic Pharmaceuticals & Consumer Health | Healthcare |
| Industry | N/A | Drug Manufacturers - General |
| Core business | Perrigo is a leading manufacturer of store-brand (private label) OTC healthcare products and generic pharmaceuticals, producing consumer health products across pain relief, cough and cold, allergy, digestive health, and other categories for retailers to sell as their own-brand alternatives to national brands. | Amgen is one of the world's largest biotechnology companies, developing and marketing innovative biological medicines across oncology (Blincyto, Lumakras), cardiovascular (Repatha), inflammation (Enbrel, Otezla), and rare disease, while also building a biosimilars business. |
| Investor focus | Investors track Perrigo's consumer self-care segment revenue growth, generic pharmaceutical business performance, margins across its product mix, and the company's path to profitability improvement following its strategic refocus on consumer health. | Investors track Amgen's product revenue growth from newer products (Repatha, Otezla, Lumakras) offsetting mature product erosion (Enbrel biosimilar competition), pipeline success rates, and biosimilar revenue contribution from its own portfolio. |
PRGO strengths
- →Private label OTC pharmaceuticals provide retailers with higher-margin alternatives to national brands — a structurally advantaged position as retailers prefer private label
- →Scale in OTC manufacturing allows Perrigo to offer cost-efficient production for numerous consumer healthcare categories
- →Consumer health is a resilient spending category — cold medicine, pain relievers, and allergy products are purchased through economic cycles
AMGN strengths
- →Diversified portfolio across multiple therapeutic areas reduces single-product concentration risk
- →Repatha cardiovascular and Otezla dermatology/inflammation provide multi-billion dollar growth platforms
- →Horizon Therapeutics acquisition added rare disease assets including Tepezza (thyroid eye disease) as a high-value specialty franchise
Risks to watch — PRGO
- →Generic OTC pharmaceutical pricing faces constant pressure from competition and retailer bargaining power
- →Perrigo has undergone significant strategic restructuring and management changes, creating operational uncertainty
- →Regulatory compliance in pharmaceutical manufacturing is complex and can be costly to maintain across its global facilities
Risks to watch — AMGN
- →Enbrel faces biosimilar competition as market exclusivity expires, pressuring one of its historically largest revenue contributors
- →Pipeline R&D success rates are inherently unpredictable — clinical trial failures can materially affect Amgen's near-term earnings outlook
- →Pharmaceutical pricing pressure from government negotiation programs (IRA) could affect future drug pricing for Amgen's branded products
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →